Sean Kelly is an accomplished Oncology Institutional Specialist at Pfizer, bringing over three decades of extensive experience in pharmaceutical and biologic sales. His impressive career has been marked by a proven track record of success across a diverse range of therapeutic areas, including Oncology, Hematology,...
Sean Kelly is an accomplished Oncology Institutional Specialist at Pfizer, bringing over three decades of extensive experience in pharmaceutical and biologic sales. His impressive career has been marked by a proven track record of success across a diverse range of therapeutic areas, including Oncology, Hematology, Psychiatry, Neurology, and more. In his current role, Sean has distinguished himself as a leader within the Pfizer Oncology team, achieving remarkable recognition as the number one ranked Oncology Institutional Specialist in the nation for the first semester of 2024.
Sean's expertise is particularly evident in his management of key projects such as the promotion of Adcetris for lymphoma treatment, where he has effectively communicated the product's value to healthcare professionals, driving significant adoption and patient outcomes. His territory in Philadelphia is a powerhouse, contributing over 50% of Elrexfio's volume in the Mid-Atlantic District, underscoring his strategic impact on the organization’s growth and market presence.
In addition to his sales achievements, Sean has excelled in driving growth for Besponsa (Inotuzumab), where he ranked number one in the nation for percentage growth in 2023 among the Oncology Institutional Specialist team. His ability to navigate complex healthcare environments and build strong relationships with physicians, pharmacists, and hospital administrators has been instrumental in his success. Sean's comprehensive understanding of the pharmaceutical industry, combined with his skills in sales operations and strategic account management, positions him as a key player in advancing Pfizer's mission to improve patient outcomes in oncology. As he continues to lead initiatives that enhance treatment options and access for patients, Sean remains committed to excellence in the ever-evolving landscape of oncology care.
